G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
96 hedge funds and large institutions have $51.5M invested in G1 Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 31 closing their positions.
256% more call options, than puts
Call options by funds: $431K | Put options by funds: $121K
14% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 36
17% less funds holding
Funds holding: 116 → 96 (-20)
58% less capital invested
Capital invested by funds: $124M → $51.5M (-$72.6M)
61% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.3M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.67M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.33M |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$1.19M |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$923K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.83M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$3.53M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$3.5M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$2.01M |
| 5 |
CA
CHI Advisors
New York
|
-$1.81M |
GTHX Hedge Fund Activity: Q1 2023 in Review
96 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q1 2023, worth a combined $51.5M — down 58% from $124M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of GTHX and 12 opened new positions — a net loss of 19 holders — while 36 trimmed existing stakes and 31 added.
The largest buyer was Fidelity Investments, adding an estimated $3.3M. The largest seller was Millennium Management, cutting an estimated $3.83M.
- 96 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q1 2023, down from 116 in Q4 2022.
- Funds reported $51.5M of G1 Therapeutics, Inc. Common Stock stock for Q1 2023, down 58% quarter-over-quarter.
- 12 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q1 2023 and 31 closed out, a net change of -19 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q1 2023 was Fidelity Investments, an estimated $3.3M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q1 2023 was Millennium Management, an estimated $3.83M sold.
Based on aggregated 13F filings for Q1 2023.